Showing results (251-260 of 352) with videos related to
Sort By:
Pageof 36
Journal of the American Academy of Dermatology|December 25, 2019
Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathwaysMichelle S Min, Jianni Wu, Helen He, et al.Dermatology and Therapy|March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical TrialsRui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.Dermatology and Therapy|December 8, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHTApril Armstrong, Kim A Papp, Mark Lebwohl, et al.Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.Dermatology and Therapy|March 21, 2025
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis TrialsApril W Armstrong, Leon Kircik, Linda Stein Gold, et al.Dermatology Online Journal|October 31, 2025
A review of the safety, efficacy, and administration of hedgehog inhibitors for the treatment of advanced basal cell carcinoma: an expert consensus panelMilaan Shah, Lauren Debusk, Angela Rosenberg, et al.Dermatology and Therapy|December 12, 2022
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)Paolo Gisondi, Alice B Gottlieb, Boni Elewski, et al.JAAD International|July 23, 2024
Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panelBrian Berman, April Armstrong, Mark Lebwohl, et al.The Journal of Dermatological Treatment|April 6, 2018
Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Guy Shalom, Luigi Naldi, Mark Lebwohl, et al.Lancet (London, England)|July 13, 2020
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trialDavid Rosmarin, Amit G Pandya, Mark Lebwohl, et al.Pageof 36